Related Experiment Video

Updated: Sep 27, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K

Deep Brain Stimulation for a Patient with Familial Parkinson's Disease Harboring CHCHD2 p.T61I

Hikaru Kamo1, Genko Oyama1,2,3,4,5,6, Kenya Nishioka1

  • 1Department of Neurology Juntendo University Graduate School of Medicine Tokyo Japan.

Movement Disorders Clinical Practice
|April 11, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CHCHD2deep brain stimulationfamilial Parkinson's disease

More Related Videos

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

14.9K
Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
09:46

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

Published on: March 8, 2015

11.1K

Related Experiment Videos

Last Updated: Sep 27, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.6K
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
07:14

A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test

Published on: May 31, 2016

14.9K
Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
09:46

Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus

Published on: March 8, 2015

11.1K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

414
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
414

Articles linked to this work by shared authors, journal, and citation graph.

Astrocyte-Predominant Tau Pathology in a Patient With VCP R191Q Variant.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026

How Do Oral Medications, Botulinum Toxin Use, and Treatment Burden Change after Deep Brain Stimulation for Dystonia?

Movement disorders clinical practice·2026

Levodopa-induced alterations in vertical center of mass and muscle synergy structure during Parkinsonian gait.

Experimental brain research·2026

Rehabilitation strategies for atypical parkinsonian syndromes: A scoping review of progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome, and dementia with Lewy bodies.

Journal of Parkinson's disease·2026

A PARK9 iPSC-Derived Dopaminergic Neuron Model Enables Drug Screening Targeting Autophagy-Lysosome Pathway Dysfunction in Parkinson's Disease.

Journal of neurochemistry·2026

Pontine Hemorrhage Mimicking Bell's Palsy: Isolated Facial Nerve Palsy-A Case Report.

Case reports in neurological medicine·2026

Should Paratonia Be Considered a Movement Disorder? Implications for Clinical Management.

Movement disorders clinical practice·2026

Initial Experience with Pseudomonopolar Local Field Potentials in Deep Brain Stimulation for Parkinson's Disease.

Movement disorders clinical practice·2026

Fluid Intelligence and Executive Dysfunction in Progressive Supranuclear Palsy.

Movement disorders clinical practice·2026

Clinical Outcomes with Chronic Adaptive Versus Conventional DBS in Parkinson's Disease: A Pilot Randomized Crossover Trial.

Movement disorders clinical practice·2026

Phenotypic Spectrum and Clinical Approach to Early-Onset Hereditary Spastic Paraplegia.

Movement disorders clinical practice·2026

Understanding Neuropsychiatric Fluctuations in Parkinson's Disease: From Mechanisms to Management.

Movement disorders clinical practice·2026

HER2-Targeted AIE Nanotheranostics Overcome SHR-A1811 Resistance via Immunogenic Pyroptosis and Tumor-Associated Macrophage Reprogramming in Breast Cancer.

Small (Weinheim an der Bergstrasse, Germany)·2026

Systemic administration of the PRMT5 inhibitor GSK3326595 does not induce overt cardiotoxicity in the murine heart.

Journal of molecular and cellular cardiology plus·2026

Promotion or suppression? Does internet use by the Chinese public affect physician trust?

Frontiers in public health·2026

The Phosphate-Specific Transport System Gene pstA1 Contributes to Rifampin Tolerance in Mycobacterium tuberculosis.

The Journal of infectious diseases·2026

Could thiamine supplementation delay the progression of retinal dystrophy in Rogers syndrome?

Ophthalmic genetics·2026

Treat-to-target: LLDAS, DORIS remission, and flare prevention strategies.

Rheumatology (Oxford, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us